Position in AGMB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$21,538,414
New position
Shares Held
2,053,233
first reported quarter
Ownership
4.17%
of shares outstanding
% of Portfolio
0.62%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026TCG Crossover Management, LLC holds $3,218,747,876 across 44 Biotechnology names. AGMB ranks #30 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
6,481,085 | $721,668,814 | |
| 2 | CGON |
CG Oncology, Inc.
|
3,670,206 | $248,399,542 | |
| 3 | TNGX |
Tango Therapeutics, Inc.
|
10,531,071 | $220,310,005 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
4,946,894 | $190,405,950 | |
| 5 | CNTA |
Centessa Pharmaceuticals plc
|
4,286,480 | $170,258,985 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,676,624 | $140,702,286 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
3,248,980 | $124,435,934 | |
| 8 | IMVT |
Immunovant, Inc.
|
4,457,988 | $110,736,421 |
All Filings in AGMB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $21,538,414 | 2,053,233 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||